drugset / Trial / NCT06153368
Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single arm, single center, phase II study of cadonilimab plus mFOLFIRINOX as conversion therapy in patients with locally advanced pancreatic cancer.
Timeline
- Start
- 2023-12-19
- Primary completion
- 2024-11-27
- Completion
- 2025-11-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Irinotecan | Small molecule | 150 mg/m2 | Intravenous |
| Subject | Leucovorin | Small molecule | 400 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 2.4 g | — |